Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Are paclitaxel-eluting stents safe and effective in patients with acute coronary syndromes?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 566–567 (2005)Cite this article

boxed-textMoses JW et al. (2005) Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45: 1165–1171

The use of drug-eluting stents should be recommended for patients with acute coronary syndromes

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. FRagmin and Fast Revascularization during InStability in Coronary artery disease Investigators (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease. FRISC II prospective randomised multicenter study. Lancet 354: 708–715

  2. Cannon CP et al.; TACTICS TIMI 18 Investigators (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with tirofiban. N Engl J Med 344: 1879–1887

    Article  CAS  Google Scholar 

  3. Fox KA et al. (2002) Interventional versus conservative treatment for patients with unstable angina or non-ST myocardial infarction; The British Heart Foundation RITA-3 randomised trial. Lancet 360: 743–751

    Article  CAS  Google Scholar 

  4. Lemos PA et al. (2003) Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. J Am Coll Cardiol 41: 2093–2099

    Article  Google Scholar 

  5. Zahn R et al.; German Cypher Stent Registry (2005) Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry). Am J Cardiol 95: 1302–1308

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Interventional Cardiology,

    J Eduardo Sousa

  2. Cardiologist,

    Eduardo Missel

  3. Chief of Coronary Intervention,

    Alexandre Abizaid

  4. Director of the Division of Diagnostic and Interventional Cardiology at the Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil

    Amanda Sousa

Authors
  1. J Eduardo Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Missel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandre Abizaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amanda Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Eduardo Sousa.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sousa, J., Missel, E., Abizaid, A. et al. Are paclitaxel-eluting stents safe and effective in patients with acute coronary syndromes?. Nat Rev Cardiol 2, 566–567 (2005). https://doi.org/10.1038/ncpcardio0365

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0365

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing